Position in NVO
as of Jun 30, 2026
· filed Aug 7, 2026
Position Value
$25,041,411
-$12,728,328 QoQ
Shares Held
522,349
-49.2% QoQ
Ownership
0.012%
of shares outstanding
% of Portfolio
0.25%
of 13F equity value
Holder Rank
#83
of 1,348 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in NVO Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Quadrature Capital Ltd holds $269,077,008 across 11 Drug Manufacturers - General names. NVO ranks #5 (9.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
75,764 | $90,873,622 | |
| 2 | ABBV |
AbbVie Inc.
|
212,852 | $53,562,077 | |
| 3 | NVS |
Novartis AG
|
240,579 | $37,703,540 | |
| 4 | AZN |
Astrazeneca PLC
|
157,534 | $29,871,597 | |
| 5 | NVO |
Novo Nordisk A S
This page
|
522,349 | $25,041,411 | |
| 6 | PFE |
Pfizer Inc
|
978,887 | $23,571,598 | |
| 7 | SNY |
Sanofi
|
60,025 | $2,560,666 | |
| 8 | MRK |
Merck & Co., Inc.
|
15,260 | $1,960,910 |
All Filings in NVO
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $25,041,411 | 522,349 | Shares | Other | 2026-08-07 | |
| 2026-03-31 | $37,769,739 | 1,027,748 | Shares | Other | 2026-05-15 | |
| 2025-12-31 | $59,882,351 | 1,176,933 | Shares | Other | 2026-02-17 | |
| No filing history on record for this holder in this stock. | ||||||